HomeTOP STORIESSkye plummets 60% on mid-stage data for nimacimab for weight loss Skye plummets 60% on mid-stage data for nimacimab for weight loss By rogerjudd October 6, 2025 FacebookTwitterPinterestWhatsApp Post Content Previous articleLeap Therapeutics secures $58.9M PIPE to launch digital asset strategy; shares up 29%Next articleBiggest stock movers Monday: MU, QUBT, AMD, crypto stocks, and more latest articles The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds explore more The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds
